The Rising Cost of AI Enterprises Face a Tokens or Humans Dilemma as Budgets Burn Through APVO Q1 2026 Earnings EPS Misses Estimates as PreRevenue Biotech Faces Headwinds Investor Skepticism Clouds StateLed Turnaround for China Vanke